Press Releases

Press Releases

Press Releases

Date Title and Summary Additional Formats
Nov 06, 2018
Genomic Health Announces Record Revenue and Profit in Third Quarter 2018 Financial Results; Raises Full Year Guidance
REDWOOD CITY, Calif. , Nov. 6, 2018 /PRNewswire/ -- Genomic Health , Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter ended September 30, 2018 . "We continue to deliver record results in 2018, including 23 percent revenue growth and $12 million in profit
Oct 30, 2018
Genomic Health to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 6, 2018
REDWOOD CITY, Calif. , Oct. 30, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ:  GHDX) today announced that the company will host a conference call and webcast on Tuesday, November 6 at 4:30 p.m. Eastern Time to discuss its third quarter 2018 financial results.
Oct 29, 2018
Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castrate Resistant Prostate Cancer Effective December 10
Medicare coverage supports clinical utility of the Oncotype DX AR-V7 Nucleus Detect test, providing 25,000 Medicare patients with coverage SAN DIEGO and REDWOOD CITY, Calif. , Oct. 29, 2018 /PRNewswire/ --  Epic Sciences, Inc. (Epic) and Genomic Health, Inc.
Oct 22, 2018
Genomic Health Announces Multiple Studies Reinforcing Value of Oncotype DX® Tests in Guiding Treatment for Breast and Prostate Cancer Patients
Studies Presented at ESMO 2018 Congress Underscore Growing Clinical Evidence Across Genomic Health's Test Portfolio REDWOOD CITY, Calif. , Oct. 22, 2018 /PRNewswire/ --  Genomic Health , Inc. (Nasdaq: GHDX) today announced results from multiple studies of its Oncotype DX ® tests highlighting their
Sep 28, 2018
New Published Data and Recent Positive Private Payor Coverage Decisions Underscore Value and Utility of the Oncotype DX Genomic Prostate Score® (GPS™) Test
New Analysis from Unprecedented Study of Patient Medical Records from Large Private U.S. Health Insurer Reconfirms Active Surveillance Increases by 30 Percent in Patients Using GPS™ Test, Improving Adherence to Guideline-based Treatment New Publication Showing Test's Value Independent of MRI and
Aug 02, 2018
Genomic Health Announces Second Quarter 2018 Financial Results and Reports Recent Business Progress
Reported Record Revenue of $95.6M and Delivered 14 Percent Growth on a Pre-606 Adjusted Revenue Basis Delivered $8.3M Profit on a GAAP Basis and $9.4M Profit on a Non-GAAP Basis 12th Consecutive Quarter of Improved Non-GAAP Profitability REDWOOD CITY, Calif. , Aug.
Jul 26, 2018
Genomic Health to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 2, 2018
REDWOOD CITY, Calif. , July 26, 2018 /PRNewswire/ --  Genomic Health, Inc.  (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Thursday, August 2 at 4:30 p.m. Eastern Time to discuss its second quarter 2018 financial results. The call and webcast will follow
Jun 03, 2018
Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Demonstrate the Oncotype DX Breast Recurrence Score® Test Definitively Identifies the 70% of Women with Early-stage Breast Cancer Who Receive No Benefit from Chemotherapy, and the 30% of Women for Whom Chemotherapy Benefit Can be Life-saving
Independently Led by ECOG-ACRIN Research Group, TAILORx Prospective, Randomized Phase III Clinical Trial Results to be Presented Today in the Plenary Session at ASCO Annual Meeting TAILORx-defined Cutoff for Definitively Determining Chemotherapy Benefit with Oncotype DX® Usher in a New Era in the
May 30, 2018
Genomic Health to Present at Jefferies 2018 Global Healthcare Conference
REDWOOD CITY, Calif. , May 30, 2018 /PRNewswire/ --  Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present at the Jefferies 2018 Global Healthcare Conference in New York City on Wednesday, June 6, 2018 at 8:30 a.m. Eastern Time . To access the live and subsequently archived
May 21, 2018
New Data Reinforce Positive Impact of the Oncotype DX® Genomic Prostate Score™ Test in Guiding Treatment Decisions
Studies in Over 30,000 Newly Diagnosed Prostate Cancer Patients Presented at American Urological Association (AUA) Annual Meeting Confirm Utility of GPS™ Test in Optimizing Cancer Care REDWOOD CITY, Calif. , May 21, 2018 /PRNewswire/ -- Genomic Health , Inc. (NASDAQ: GHDX) today announced results